“The Use of CGM in Non-Insulin Treated T2D and Pre-t2d” (Hybrid Event)

Tadej Battelino, MD, PhD
UCH, University Medical Center Ljubljana, Slovenia
Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Tadej Battelino completed his medical degree at the University of Ljubljana in 1990. He completed a PhD focusing on glucose metabolism in neonatal endotoxic shock in 1996. He completed his clinical fellowship at Loyola University of Chicago, USA, and his postdoctoral fellowship at INSERM, Paris, France.

Professor Battelino is currently Consultant and Head of Department of Endocrinology, UCH-UMC Ljubljana, a clinical pharmacologist, Head, Chair of Pediatrics, and Professor of Paediatrics at Faculty of Medicine, University of Ljubljana. He is PI on several publicly funded research projects in the field of diabetes, endocrinology and metabolism, and was awarded the Slovene national award for research in 2014, Gold medal for research at the University of Ljubljana in 2017, the ISPAD Achievement Award in 2020, the Presidential Medal from Children with Diabetes society in 2022, and the European Society for Pediatric Endocrinology (ESPE) research award in 2023. Professor Battelino serves on the editorial boards for the journals Diabetes Care, Diabetes Technology and Therapeutics, Journal of Pediatric Endocrinology and Metabolism, Acta Diabetologica, and was Editor for the European Journal of Endocrinology from 2009 to 2015. He has authored or co-authored over 350 papers in international peer-reviewed journals and participated chapters to several international books. He has the h index of 63.

Professor Battelino is a member of numerous professional associations including the American Diabetes Association (ADA), European Society for Paediatric Endocrinology (ESPE) and the International Society for Pediatric and Adolescent Diabetes (ISPAD), for which he served as President for the 35^th Annual Congress. He served on the European Association for the Study of Diabetes (EASD) council, and is co-organizer of sixteen annual meetings of the Advanced Technologies and Treatment of Diabetes – ATTD. He serves as Chair-Elect International Diabetes Federation – Europe (IDF-EU 2022-2024). He is elected Honorary member of the Italian Society for Pediatric Endocrinology and Diabetology (SIEDP) and the Hellenic Society of Pediatric and Adolescent Endocrinology (EEPEE).  Professor Battelino is a member of the Slovenian Medical Academy, Slovenian Academy of Sciences and Arts (SAZU),  and the European Academy of Sciences and Arts.

______________________________________________________________________________________________________________________________________

Dr. Battelino’s Objectives:

• Explain with the benefits of CGM usage in T2D
• Debate the potential advantages of using CGM in managing non-insulin treated T2D
• Evaluate the potential use of CGM for determining remission of pre-T2D and T2D

Faculty Disclosure

Dr. Battelino has indicated the following relevant financial relationships with commercial interests:

Financial Relationship                                    Commercial Interest/Organization
Researcher                                                         Sanofi, Novo Nordisk, Medtronic
Speaker                                                               Eli Lilly, Novo Nordisk, Sanofi, Medtronic,  Abbott, Dexcom, AstraZeneca

Planning Committee Disclosure

Dr. Deshpande has indicated that he has no relevant financial relationships with commercial interests.

Dr. Weiss has indicated the following relevant financial relationships with commercial interests:
Financial Relationship                                     Commercial Interest/Organization
Consultant/Contractor                                       Prizm LLC

All the relevant financial relationships for these individuals have been mitigated.

Target Audience
Primary care physicians.

Accreditation
The University of Miami Leonard M. Miller School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The University of Miami Leonard M. Miller School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.